Keywords: Roche, Genentech, FORMA Theerapeutics, Preclinical cancer program
Roche’s Genentech in preclinical cancer program deal with FORMA Therapeutics
Article | 28 June 2011
Cambridge, Massachusetts, USA-based small-molecule therapeutics developer FORMA Therapeutics has entered into an agreement granting Genentech, Swiss drug major Roche’ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
